Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumoursLoren Lasko, Kenneth D. Bromberg, T. Matt Hansen et al.|Nature|2017Cited by 853
ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor ModelsCherrie K. Donawho, David J. Frost, Yan Luo et al.|Clinical Cancer Research|2007Cited by 770
Activity of the Bcl-2 Family Inhibitor ABT-263 in a Panel of Small Cell Lung Cancer Xenograft ModelsAlex R. Shoemaker, Steven W. Elmore, Michael J. Mitten et al.|Clinical Cancer Research|2008Cited by 209